Skip to content
Agentic OS
Menu

Intelligence / Healthtech / New Clinical Trials / AbbVie

Clinicaltrial registered26 Oct 2026

AbbVie

26 Oct 2026: Trial registered · A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) ABBV-706 in Combination With Alveltamig and Atezolizumab for Adults Participants With Extensive Stage-Small Cell Lung Cancer. Recorded in the ClinicalTrials.gov (US National Library of Medicine).

View the source record

Posted
26 Oct 2026
Title
A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) ABBV-706 in Combination With Alveltamig and Atezolizumab for Adults Participants With Extensive Stage-Small Cell Lung Cancer
Conditions
Extensive Stage-Small Cell Lung Cancer (ES-SCLC)
Phase
Phase 2
Study Type
Interventional
Status
Not Yet Recruiting
Reference
NCT07895043
What this signal means

A new trial needs sites, patients, data capture, monitoring and regulatory partners for years.

  1. United States leads with 192 of 777, then China (171).
  2. 777 added in the 30 days to 18 Nov 2026.
Reach them with AOS

Find the decision makers at AbbVie

AOS maps the buying committee, finds verified work emails and drafts outreach that cites this clinical signal, for your approval.

Start free

Across AOS Research

Other records for AbbVie in our registers.

Source: ClinicalTrials.gov (US National Library of Medicine), data to 18 Nov 2026. Trials first posted in the window whose lead sponsor is a company, worldwide. Device and diagnostic studies usually have no phase. AOS shows what the public record says; it does not verify or endorse the company.